Edwards Lifesciences (EW) News Today

Edwards Lifesciences Corporation (NYSE: EW) is seeing mixed analyst activity and regulatory developments driving today’s trading. Below are the key updates impacting the stock:

• Positive Sentiment: Wells Fargo raised its price target on EW from $84.00 to $88.00 and maintained an “overweight” rating, implying roughly 13.1% upside. Read More
• Neutral Sentiment: GuruFocus published a strategic SWOT analysis of Edwards Lifesciences, examining its financial health and market positioning. Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insight
• Negative Sentiment: The U.S. Federal Trade Commission sued to block EW’s $380 million acquisition of JenaValve, citing competition concerns in aortic regurgitation devices. FTC seeks to block Edwards Lifesciences' acquisition of JenaValve
• Negative Sentiment: Multiple outlets report the FTC has formally blocked the proposed JenaValve deal, marking a significant regulatory hurdle. FTC Blocks Edwards Lifesciences' Proposed Acquisition of JenaValve Technology
• Negative Sentiment: TipRanks and Seeking Alpha cover the FTC’s lawsuit to halt the JenaValve purchase, emphasizing legal setbacks for EW. FTC Blocks Edwards Lifesciences’ Acquisition of JenaValve FTC sues to block Edwards Lifesciences purchase of JenaValve
• Negative Sentiment: JenaValve issued a response to the FTC’s action, warning the block could limit treatment options for aortic regurgitation patients. JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
• Negative Sentiment: Edwards Lifesciences issued a statement disagreeing with the FTC’s decision, arguing it will impede innovation and patient access. Edwards Lifesciences Comments on FTC’s Action
• Negative Sentiment: Benzinga warns that EW shares may trade sluggishly through 2027, suggesting limited upside despite avoiding a outright bearish trend. Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027